Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Abbott Laboratories vs. Novo Nordisk

By David Jagielski – Feb 13, 2020 at 8:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These healthcare stocks can give investors a good mix of dividends and growth.

As enticing as new up-and-coming biotech stocks may be, the safer and potentially better long-term play for investors is to buy shares of more established brands. Both Novo Nordisk (NVO) and Abbott Laboratories (ABT) are great examples, with market caps of around $150 billion each.

These healthcare giants are mature companies that have no problem recording profits and even paying dividends -- and won't take investors on wild rides. Choosing between the two stocks can be difficult, however, as they focus on different areas and also possess different risks. Let's take a closer look at the two to see which stock is the better buy today.

Abbott's strength is its diversification

For investors who are in search of consistency, Abbott Laboratories offers a strong mix of dividends and growth that other stocks simply can't beat. The medical device company has a variety of products that allows it to continue growing -- cardiovascular and neuromodulation, diagnostic, and nutritional. From glucose monitors to infant formula and to its popular Ensure brand of nutritional products, Abbott is a well-diversified stock that isn't dependent on one area or segment to continue growing.

The company is coming off a strong fourth quarter where it beat analyst expectations for revenue with growth of 7.1%, as the company's medical device segment and its pharmaceuticals segment were both up 10% year over year. What's encouraging is that not only is the company still growing, it's also not standing pat as it continues to develop new devices. Abbott announced in February that the Food and Drug Administration approved a trial for the company's Amplatzer Amulet device, which looks to help people with atrial fibrillation and reduce their risk of stroke and bleeding.

A plastic pill bottle tipped over with pills spilling out.

Image source: Getty Images

Abbott looks like a good buy even before discussing what may be most attractive about the stock: its dividend. With a solid track record of paying dividends that includes increasing payouts for 40-plus years, Abbott becomes an even better buy when factoring in the recurring income you can expect to hold from owning shares of the company. Admittedly, its quarterly dividend of $0.36 will only produce a modest dividend yield of 1.65%, which is below the S&P 500 average of 1.85%. The real value is from holding over the long term and seeing the dividend payments rise over time. Investors who have held shares of the stock since 2013 have seen their dividend payments more than double from the $0.14 that Abbott was paying back then.

Novo is comparable, but with a focus on diabetes

Novo Nordisk has a lot in common with Abbott, as it also offers a strong dividend and is still showing good growth. The company released its fourth-quarter results on Feb. 5, and while it generated 9% sales growth during the quarter, the company expects its growth rate, without the impact of foreign exchange, to grow between 3% and 6% in 2020. One difference from Abbott is Novo's revenue mix is not as diverse, with 84% of the company's revenue in Q4, as well as for the entire year, coming from diabetes and obesity care products. Novo's biopharma segment contributed the remaining 16% of its sales.

In addition to having less diversification, the Danish company also has more exposure to foreign exchange. Although its Q4 numbers saw 9% sales growth from the prior year, at constant exchange rates, that growth was more modest, at just 6%. Without foreign exchange, its diabetes and obesity segment rose by 7% in Q4 while biopharma sales were up 2%.

Novo pays a dividend of around 2% per year, and it too has increased its dividend payments annually -- although, with just more than 10 years of consecutive increases to its payouts, it's nowhere near Abbott's impressive track record.

Which stock is the better buy today?

Both of these stocks look to be attractive long-term buys, and in three years both have outperformed the Health Care Select Sector SPDR ETF:

ABT Chart

ABT data by YCharts.

There isn't a lot separating them and that's where valuation can help break the tie. Abbott is trading at a forward price-to-earnings ratio of 22, which is slightly less than the 24 times investors are valuing Novo at today. With a slightly better valuation, more diversification in its revenue, and less foreign-exchange risk, Abbott is the better buy of these two healthcare stocks, but not by much.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
Novo Nordisk Stock Quote
Novo Nordisk
NVO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.